Quick Comparison
| HGH Fragment 176-191 | Tirzepatide | |
|---|---|---|
| Half-Life | 0.5-1 hours | 120 hours (5 days) |
| Typical Dosage | Research: 250-500 mcg subcutaneous once or twice daily, on an empty stomach. Often cycled 8-12 weeks on, 4 weeks off. The short half-life typically requires twice-daily dosing for sustained effect. | Weight management (Zepbound): 2.5 mg subcutaneous once weekly for 4 weeks, increasing by 2.5 mg every 4 weeks to maintenance dose of 5-15 mg once weekly. Diabetes (Mounjaro): same escalation schedule, maintenance 5-15 mg subcutaneous once weekly. |
| Administration | Subcutaneous injection | Subcutaneous injection (weekly) |
| Research Papers | 1 papers | 30 papers |
| Categories |
Mechanism of Action
HGH Fragment 176-191
HGH Fragment 176-191 is the unmodified C-terminal segment of human growth hormone, representing exactly the last 16 amino acids of the 191-amino-acid GH molecule. Research identified this region as containing the molecular determinants responsible for GH's lipolytic activity, independent of the N-terminal domain that binds the growth hormone receptor and drives IGF-1 production and tissue growth.
The fragment activates lipolysis in white adipose tissue through interaction with beta-adrenergic signaling pathways. This triggers the cAMP/protein kinase A cascade that phosphorylates and activates hormone-sensitive lipase and perilipin proteins on the surface of lipid droplets within fat cells. The result is the breakdown of stored triglycerides into free fatty acids and glycerol, which are released into circulation for oxidation by energy-demanding tissues such as skeletal muscle and the liver.
Because the fragment lacks the binding regions for the GH receptor (located in amino acids 1-175), it does not activate the JAK2-STAT5 signaling pathway responsible for hepatic IGF-1 synthesis, somatic growth, or the insulin-antagonistic effects of full-length growth hormone. However, the shorter half-life compared to AOD-9604 (which has an additional stabilizing tyrosine residue) means more frequent dosing is required, and clinical evidence supporting its efficacy in humans remains very limited.
Tirzepatide
Tirzepatide is the first approved dual incretin receptor agonist, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism represents a paradigm shift in obesity and diabetes treatment because the two receptor systems produce complementary and additive metabolic effects that neither achieves alone.
The GLP-1 receptor component works similarly to semaglutide — suppressing appetite through hypothalamic signaling, slowing gastric emptying, and stimulating glucose-dependent insulin secretion. However, the addition of GIP receptor agonism provides unique benefits. GIP receptors in adipose tissue enhance lipid metabolism and may improve fat storage efficiency, while GIP signaling in the brain appears to amplify the appetite-suppressing effects of GLP-1 through distinct neuronal circuits in the hypothalamus.
At the pancreatic level, the dual stimulation of both GIP and GLP-1 receptors on beta cells produces a more robust insulin secretory response than either pathway alone. Tirzepatide also improves insulin sensitivity in peripheral tissues, reduces hepatic fat content, and lowers triglyceride levels. The molecule is built on a modified GIP peptide backbone with GLP-1 receptor cross-reactivity, attached to a C20 fatty di-acid moiety that enables albumin binding and weekly dosing. Clinical trials have shown weight loss of up to 22.5% of body weight, surpassing GLP-1-only agents.
Risks & Safety
HGH Fragment 176-191
Common
injection site irritation, headache, brief dizziness.
Serious
extremely limited clinical data, no long-term safety information.
Rare
allergic reactions.
Tirzepatide
Common
nausea (25-35%), diarrhea, constipation, vomiting, reduced appetite, stomach pain, redness at injection site.
Serious
inflammation of the pancreas (pancreatitis), gallstones, very slow stomach emptying (gastroparesis), low blood sugar if combined with other diabetes medications.
Rare
thyroid tumours seen in animal studies, severe allergic reactions, kidney problems.
Full Profiles
HGH Fragment 176-191 →
The original, unmodified version of the growth hormone fat-burning fragment — essentially the same concept as AOD-9604 but less stable and shorter-lasting. Contains the part of growth hormone responsible for fat metabolism without the parts that cause growth or blood sugar issues. Requires more frequent dosing than AOD-9604, and has even less clinical evidence supporting its effectiveness.
Tirzepatide →
Sold as Mounjaro and Zepbound, this is one of the most effective weight loss medications available. It works by targeting two appetite hormones at once (GIP and GLP-1), making it more powerful than medications like semaglutide that only target one. People in clinical trials lost up to 22.5% of their body weight. Also FDA-approved for type 2 diabetes, and improves cholesterol and blood fat levels.